Postoperative Sequential Mitomycin-C, Vinblastine, and Cisplatin (MVP) Chemotherapy and Radiotherapy for Resected Stage II-IIIA Non-small Cell Lung Cancer.
- Author:
Tae Won KIM
1
;
Jung Shin LEE
;
Byung Hak JUNG
;
Hwan Jung YUN
;
Dae Young ZANG
;
Je Hwan LEE
;
Sung Bae KIM
;
Sang We KIM
;
Cheolwon SUH
;
Kyoo Hyung LEE
;
Woo Kun KIM
;
Won Dong KIM
;
Jong Hoon KIM
;
Eun Kyung CHOI
;
Hyesook CHANG
;
Dong Kwan KIM
;
Seung II PARK
;
Kwang Hyun SOHN
;
Sang Hee KIM
Author Information
1. Department of Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Postoperative chemotherapy;
Postoperative radiotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Cisplatin*;
Disease-Free Survival;
Drug Therapy*;
Drug Therapy, Combination;
Esophagitis;
Female;
Follow-Up Studies;
Humans;
Male;
Mitomycin*;
Neoplasm Metastasis;
Neutropenia;
Prospective Studies;
Radiation Pneumonitis;
Radiotherapy*;
Recurrence;
Survival Rate;
Vinblastine*
- From:Korean Journal of Medicine
1998;54(5):607-614
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The poor survival rates among patients receiving surgery alone for stages II and III non-small cell lung cancer prompted several trials of adjuvant therapy after resection. We performed a prospective phase II study in patients with stage II-IIIA non-small cell lung cancer after resection to evaluate the feasibility, activity and toxicity of the postoperative sequential MVP chemotherapy and radiotherapy. METHODS: Between February 1991 and May 1995, 60 patients with resected stage II, IIIA non-small cell lung cancer received 2 cycles of MVP combination chemotherapy (Mitomycin-C 6 mg/m2, Vinblastine 6 mg/m2, Cisplatin 60 mg/m2) within 3 weeks after surgery, followed by thoracic irradiation (5,040 cGy after complete resection and 900 cGy booster to microscopically positive resection margin at 1.8 Gy per fraction) within 3-4 weeks after chemotherapy. RESULTS: Forty nine men and 11 women with a median age of 60.5 years (range 33-81 years) were included. During the median follow-up period of 828 days (61-2,015 days), 25 patients had developed recurrence. Among the 25 failures, 3 were local relapse only and 20 were distant metastasis only and 2 had both local and distant sites of recurrence. Three-year overall survival and event-free survival were 43% and 37%, respectively. Neutropenia of grade I-II was observed only in 13 patients. Eleven patient showed grade I-II radiation pneumonitis and 32 had grade I-II radiation esophagitis. CONCLUSION: Postoperative sequential MVP chemotherapy and radiotherapy in resected stage II-IIIA non-small cell lung cancer is well-tolerated and shows interesting activity.
